Taysha Gene Therapies Files 2025 Proxy Statement
Ticker: TSHA · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1806310
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Taysha Gene Therapies filed its proxy statement for the June 2nd meeting. Vote your shares!
AI Summary
Taysha Gene Therapies, Inc. filed its definitive proxy statement on April 21, 2025, for its annual meeting on June 2, 2025. The filing covers the fiscal year ending December 31, 2024, and details matters to be voted on by shareholders, including the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information regarding corporate governance and executive compensation, enabling informed voting decisions at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material events or financial disclosures beyond what is expected for such a report.
Key Numbers
- 2024-12-31 — Fiscal Year End (The proxy statement covers the company's performance and governance for this period.)
Key Players & Entities
- Taysha Gene Therapies, Inc. (company) — Registrant
- 0001806310 (company) — Central Index Key
- 20250421 (date) — Filing Date
- 20250602 (date) — Meeting Date
FAQ
What is the purpose of a DEF 14A filing?
A DEF 14A filing, also known as a definitive proxy statement, is filed by a company to provide shareholders with information about matters to be voted on at an upcoming shareholder meeting, such as the election of directors and executive compensation.
When is Taysha Gene Therapies' annual shareholder meeting scheduled?
The annual shareholder meeting for Taysha Gene Therapies is scheduled for June 2, 2025.
What is the filing date of this proxy statement?
This definitive proxy statement was filed on April 21, 2025.
What fiscal year does this proxy statement cover?
This proxy statement covers the fiscal year ending December 31, 2024.
What is Taysha Gene Therapies' primary business?
Taysha Gene Therapies, Inc. is in the business of Biological Products (No Diagnostic Substances), as indicated by its SIC code [2836].
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding Taysha Gene Therapies, Inc. (TSHA).